Ann: Ryoncil Pricing Set and Available This Quarter, page-514

First 514 Last

Share
Profile

Follow
manishv

6,201 Posts.

252

01/03/25

16:33

Post #: 78091926
Share
Originally posted by Noob2134: ↑

Great questions mate, I was wondering some of those questions too, I have been asking Grok and Chatgpt to provide with answers here are outcome:
From Grok:
Research suggests Mesoblast has provided some clarity on manufacturing costs, but future costs remain uncertain due to scaling challenges. (only the total cost, not per unit cost)
It seems likely that insurance coverage for Mesoblast's treatment is being negotiated, with no confirmed providers yet.
The evidence leans toward Mesoblast not having treated patients with the approved product yet, but they are preparing to start soon.
Mesoblast has not provided firm revenue or sales guidance as of February 2025.
Cheaper alternatives for SR-aGVHD treatment are available, such as immunosuppressive drugs.
Insurance claim rejections are a known issue, and Mesoblast is assisting with coverage, but challenges may persist.
The research on Mesoblast's product is primarily company-funded, though vetted by the FDA and peer-reviewed.
From Chatgpt:
1, Lack of Disclosed COGS per unit suggests the company carried roughly US$23–31 million worth of Ryoncil inventory into launch (valued at production cost).
2, No major insurer has publicly “confirmed” coverage yet. insurers are expected to cover Ryoncil for its indicated use, but coverage comes with prior authorization and strict criteria. As of now, coverage is on a policy-by-policy basis (e.g. internal criteria from BCBS, Centene, etc.) rather than broad publicly announced agreements. Private payer and Medicaid negotiations are in progress, backed by Mesoblast’s outreach and support programs to facilitate reimbursement.
3. No Official Launch Patients Yet: As of early March 2025, Mesoblast has not announced any “first commercial patient” treatment.
4. No Official Revenue Guidance: Mesoblast has not provided formal revenue guidance for the next fiscal year in its public releases.
5. Ruxolitinib (Jakafi) is the main existing competitor for treating SR-aGVHD (especially in adults/teens) For pediatric patients, Ryoncil is entering an unmet market with no approved rivals. Future competition may come from other cell therapies like Cynata’s CYP-001 or novel biologics, but those are still in trials Overall, Ryoncil’s unique MSC mechanism and pediatric label give it a strong head start, with few near-term direct competitors in its niche.
6. In summary, the key insurance issues are prior authorization, potential step therapy (especially requiring steroid failure and possibly a trial of ruxolitinib in older kids), and the sheer cost prompting thorough reviews.
7. In summary, independent research on Mesoblast’s financials is available from multiple sources: sell-side equity research (Piper Sandler, Bell Potter, etc.), third-party research firms (Edison, previously), and investor commentary (Seeking Alpha, etc.).

Expand

thanks nook, grok and chatgpt. at least 3 of you cared to respond. just joking.

you know if i type in chatgpt and say i want the share price to be $10 and make it happen or is it achievable easily? it'll tailor the response to that
or if i say how is MSB not .10c and $2.50 today. this should be 10c. it'lll direct you in that way.

If ChatGPT could make me a millionaire, I'd be asking it for financial advice over a yacht in the Caribbean & also sending thank-you card to MSB holders ina gold-plated envelopes!
MSB Price at posting: $2.52 Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

CKF

Profits after tax down -88%, and shares rocket – what's going on with Collins?

MPK

Many Peaks accelerating gold hunt in Côte d'Ivoire after assay 'justification'

BRK

Bullish Brookside expands with fifth DSU at 'highly sought after' American oil and gas field

SPN

Sparc opens small-scale green H2 plant in SA, but liquidity dried up

First 514 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.58		Change 0.013(0.80%)		Mkt cap ! $2.034B

Open	High	Low	Value	Volume
$1.60	$1.60	$1.57	$3.672M	2.315M

Buyers (Bids)

No.	Vol.	Price($)
10	18925	$1.58

Sellers (Offers)

Price($)	Vol.	No.
$1.58	58883	26

View Market Depth

No.	Vol.	Price($)
5	21433	1.575
23	126311	1.570
17	94876	1.565
18	136613	1.560
16	167596	1.555

Price($)	Vol.	No.
1.580	53888	23
1.585	56643	21
1.590	126350	18
1.595	98855	10
1.600	154275	13

Last trade - 12.24pm 24/06/2025 (20 minute delay)

MSB (ASX) Chart

Ann: Ryoncil Pricing Set and Available This Quarter, page-514

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

Profits after tax down -88%, and shares rocket – what's going on with Collins?

Many Peaks accelerating gold hunt in Côte d'Ivoire after assay 'justification'

Bullish Brookside expands with fifth DSU at 'highly sought after' American oil and gas field

Sparc opens small-scale green H2 plant in SA, but liquidity dried up

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Ryoncil Pricing Set and Available This Quarter, page-514

Top Stories

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

Profits after tax down -88%, and shares rocket – what's going on with Collins?

Many Peaks accelerating gold hunt in Côte d'Ivoire after assay 'justification'

Bullish Brookside expands with fifth DSU at 'highly sought after' American oil and gas field

Sparc opens small-scale green H2 plant in SA, but liquidity dried up

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News